Envestnet Asset Management Inc. Sells 69,859 Shares of Moderna, Inc. (NASDAQ:MRNA)

Envestnet Asset Management Inc. lowered its position in Moderna, Inc. (NASDAQ:MRNA) by 69.7% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 30,314 shares of the company’s stock after selling 69,859 shares during the period. Envestnet Asset Management Inc.’s holdings in Moderna were worth $1,260,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Allworth Financial LP lifted its stake in shares of Moderna by 17.3% in the 4th quarter. Allworth Financial LP now owns 1,901 shares of the company’s stock valued at $73,000 after purchasing an additional 281 shares during the last quarter. Howard Capital Management Inc. grew its stake in Moderna by 3.1% during the 4th quarter. Howard Capital Management Inc. now owns 9,994 shares of the company’s stock worth $416,000 after buying an additional 297 shares during the last quarter. Commonwealth Equity Services LLC raised its holdings in shares of Moderna by 0.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 74,520 shares of the company’s stock worth $3,099,000 after buying an additional 345 shares during the last quarter. Larson Financial Group LLC boosted its position in Moderna by 39.1% in the fourth quarter. Larson Financial Group LLC now owns 1,266 shares of the company’s stock valued at $53,000 after buying an additional 356 shares during the last quarter. Finally, New Insight Wealth Advisors grew its holdings in Moderna by 4.4% during the fourth quarter. New Insight Wealth Advisors now owns 8,545 shares of the company’s stock worth $355,000 after acquiring an additional 358 shares during the period. Institutional investors own 75.33% of the company’s stock.

Moderna Price Performance

MRNA opened at $27.82 on Wednesday. The stock has a market capitalization of $10.76 billion, a price-to-earnings ratio of -3.00 and a beta of 2.23. The business has a 50-day moving average of $29.91 and a two-hundred day moving average of $38.08. Moderna, Inc. has a 12 month low of $23.15 and a 12 month high of $170.47.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on MRNA shares. William Blair reissued a “market perform” rating on shares of Moderna in a research note on Thursday, April 17th. Evercore ISI set a $50.00 target price on Moderna in a report on Friday, February 14th. JPMorgan Chase & Co. lowered their target price on shares of Moderna from $40.00 to $33.00 and set an “underweight” rating for the company in a research note on Friday, March 21st. Bank of America lowered their target price on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a research report on Tuesday, February 11th. Finally, Barclays cut shares of Moderna from an “overweight” rating to an “equal weight” rating and reduced their target price for the stock from $111.00 to $45.00 in a research note on Tuesday, February 18th. Four analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $58.70.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.